Table 2.
Function, regulation, or mechanism | Reference |
---|---|
Suppresses innate immunity and inflammation | [3] |
Suppresses adaptive immunity | [20] |
Upregulated after stimulation of LPS, Pam3CSK4, and TGF-β1 | [3] |
Induced by IL-1β, TNF, IFN-γ, IL-18, TGF-β, and TLR ligands | [3] |
Suppressed by GM-CSF combined with IL-4 | [3] |
Suppresses proinflammatory cytokines: IL-1α, IL-1β, IL-1Ra, IL-6, IL-8, IL-17, IL-23, TNF-α, and IFN-γ | [3, 8] |
Suppresses chemokines: MIP-2/CXCL2, CCL12/MCP-5, and BCA-1/CXCL13 | [3, 8] |
Inhibits M-GSF and GM-CSF | [3, 8] |
Increases the immunosuppressive factor TGF-β1 | [3, 8] |
Induces the expression of nitric oxide in vitro | [16] |
Inhibits DCs functions | [20] |
Attenuates T cell-mediated inflammation | [20] |
Interacts with Smad3 | [3] |
Inhibits the STATs, p38MAPK, ERK1/2, JNK, FAK, Pyk2, paxillin, NF-κB, kinase Fyn, TAK1 | [3, 8, 12, 28–30] |
Inhibits NLRP3 inflammasome | [3, 16] |
Binds to IL-18Rα to form a complex with IL-18BP, thereby reduces the activity of IL-18 | [9, 16, 33, 36] |
Binds to SIGIRR | [12, 16, 38] |
Protective factor in mouse model of LPS-induced shock | [3] |
Limits tissue injury during infections | [3, 16] |
Potential protective factor in ischemia-reperfusion injury | [44, 49, 50] |
Potential protective role in autoimmune diseases | [5, 6] |
Potential antitumor effect | [7, 13, 21, 23–25] |
Potential protective factor in cardiovascular diseases | [81, 84] |
Related to obesity and insulin resistance | [88, 89] |
TLR: Toll-like receptor. LPS: lipopolysaccharide. FAK: focal adhesion kinase. Pyk2: proline-rich tyrosine kinase 2; NLRP3: NOD-like receptor family Pyrin Domain-Containing 3. SIGIRR: single immunoglobulin IL-1 receptor related protein.